Anti-oxidant and anti-microbial properties of Pelargonium sidoides DC and Lactoferrin combination.

Running title: PEL and LAT combination properties.

Michela Terlizzi\textsuperscript{a}b, Chiara Colarusso\textsuperscript{a}, Umberto Di Maio\textsuperscript{c}, Antonino Bagnulo\textsuperscript{d}, Aldo Pinto\textsuperscript{ab} and Rosalinda Sorrentino\textsuperscript{ab}.

\textsuperscript{a}Department of Pharmacy, University of Salerno, Fisciano, SA, Italy; \textsuperscript{b}ImmunePharma srl, Fisciano, SA, Italy; \textsuperscript{c}Shedir Pharma srl, Piano di Sorrento, Italy; \textsuperscript{d}Neilos srl, Piano di Sorrento, Italy.

*Corresponding author:

Dr. Michela Terlizzi, PhD
ORCID ID: https://orcid.org/0000-0002-1871-7603

e-mail address: mterlizzi@unisa.it

Department of Pharmacy
University of Salerno
Via Giovanni Paolo II, 132
84084-Fisciano (SA)-Italy
Abstract

Lactoferrin (LAT), a multi-functional protein involved in numerous physiological functions, and the medicinal plant Pelargonium sidoides DC (PEL), have been described for their anti-inflammatory properties. Because the main advantage of natural products consists in administering them in combination rather than as single compound, we aimed to understand whether the combination of PEL and LAT, herein PELIRGOSTIM, could still prove beneficial or additive/synergistic activities during inflammatory conditions. To pursue this goal, we used macrophagic cells (J774.1) and treated them with PEL and LAT in a concentration-dependent manner. We found that PELIRGOSTIM was able to reduce the levels of reactive oxygen species (ROS) and nitrite, effects that were correlated to the release of lower levels of IL-1β after LPS treatment. In addition, the combination of PEL and LAT showed bacteriostatic activities against S. aureus and E. coli which had limited growth starting from 5 hours up to 20 hours. This effect was stronger than that observed for penicillin/streptomycin.

Our results provide PELIRGOSTIM as an innovative combination of natural products capable to prevent inflammation-, oxidative stress- and microbial-related disorders.

Keywords: Pelargonium sidoides DC; Lactoferrin; anti-inflammatory; anti-oxidant; anti-microbial activity.
Introduction

Pelargonium sidoides DC (PEL) (Geraniaceae) is an African medicinal plant, traditionally used for curing various ailments, including diarrhoea, colic, gastritis, tuberculosis, cough, hepatic disorders, menstrual complaints and gonorrhoea [1]. The common name, *umckaloabo*, represents the Zulu word describing “severe cough”. Indeed, its extracts are successfully employed in modern phytotherapy in Europe to cure infectious diseases of the respiratory tract [1].

Inspired by the healing of his tuberculosis, Charles Henry Stevens introduced this phytomedical drug to England in 1897 [2], and since then, the use of this plant has increased more and more interest because of its beneficial properties. Pharmacological studies have demonstrated the usefulness of PEL in the treatment of several disorders due to its anti-inflammatory, anti-oxidant and immunomodulatory activities [3] and its anti-proliferative effect [4]. In our very recent paper, we demonstrated that PEL together with other natural products can exert antimicrobial activities [5].

So far, many studies have been conducted on the combination of PEL with other compounds, in order to identify new synergistic or enhanced pharmacological effects. In the present study, we have investigated the anti-inflammatory, anti-oxidant and anti-microbial activity of Pelargonium sidoides DC (PEL) combined with Lactoferrin (LAT), a multi-functional protein that participates to numerous physiological functions.

LAT is a non-hemic iron-binding glycoprotein of the transferrin family [6]. It is present in many biological fluids and tissues, particularly in neutrophil granules [6]. It is involved in iron transportation, immune responses, organ morphogenesis and promotes wound healing and bone growth [7]. It has also been described as beneficial to prevent cancer [7] and to exert beneficial cardiovascular properties such as lipid reduction, antihypertensive and antithrombotic effects [8]. Moreover, its iron chelating ability underlies its anti-inflammatory, anti-oxidant and anti-microbial properties [9].

Therefore, based on the literature, the main goal of this study was to evaluate whether PEL and LAT combination could be beneficial. We found that this novel combination, PEL+LAT, herein PELIRGOSTIM, had anti-inflammatory, anti-oxidant and anti-microbial activities, and that could be an alternative therapeutic strategy to the actual antimicrobial therapy.
Materials and Methods

Sample preparation. Pelargonium sidoides DC (PEL; Cod: LIP00538), Lactoferrin (LAT) and their combination (patented as PELIRGOSTIM® with number 102018000002457) were obtained from Shedir Pharma s.r.l. as dried powder, reconstituted with bi-distilled water at the stock concentration of 10mg/ml. Specifically, the samples were tested, alone and in combination, as follows:

- Pelargonium sidoides DC (PEL; 0.01-0.1-1-10-100μg/ml)
- Lactoferrin (LAT; 0.01-0.1-1-10-100μg/ml)
- PEL (10μg/ml) + LAT (1μg/ml)

The study was conducted for nine months.

MTT assay. To assess cell viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to medium-free cells post 24 hours treatment. DMSO was used to dissolve the purple formazan crystals. The formazan concentration was determined by measuring the optical density. The data are presented as absorbance (550 nm) vs treatment.

Cells cultures. J774.1 murine macrophage cell line were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Cambrex Biosciences, Microtech, Naples, Italy) supplemented with 10% foetal bovine serum (FBS), 100 units/ml penicillin, 100 units/ml streptomycin and 2 mM L-glutamine (Cambrex Biosciences, Microtech, Naples, Italy). Cells were seeded (5x10⁴ cells/well) 24 hours before treatment. Then, cells were treated for 24 hours with PEL (0.01-0.1-1-10-100μg/ml) and LAT (0.01-0.1-1-10-100μg/ml) ± LPS (0.1μg/ml, Alexis, Vincibiochem, Italy). The following combinations have also been tested: PEL+LAT±LPS.

Cytokine measurements. IL-1β was measured in cell-free supernatants obtained from the J774.1 cultures. Time-course experiments were preliminary performed to define the optimal release of IL-1β according to a positive control, LPS±ATP (0.5mM). We found that J774.1 macrophage cell cultures released higher levels of IL-1β after 24 hours of treatment. IL-1β was detected by means of a commercially available enzyme-linked immunosorbent assay kits (ELISAs) (eBioscience, CA, USA; R&D Systems, USA). Cytokine levels were expressed as pg/ml.

DCHF-DA assay. 2',7'-Dichlorodihydrofluorescein diacetate (DCHF-DA) is a cell-permeable probe used to detect intracellular reactive oxygen species (ROS). DCHF-DA probe is non-fluorescent in its initial form but it undergoes multistep conversion inside the cell that results in the formation of fluorescent product dichlorofluorescein (DCF), in presence of intracellular ROS. Briefly, J774.1 cells were plated (10⁵ cells/well) and treated as described above for 45 minutes [10]. After the subsequent incubation with DCHF-DA 10μM for 15 minutes at 37°C, the flow-cytometry
analysis was performed (BD FacsCalibur Milan, Italy). This time point was chosen according to the capability of LPS to induce oxidative stress [11]. Data were expressed as percentage of DCHF⁺ cells.

**Nitrite assay.** J774.1 cells were plated (5x10⁴ cells/well) and treated as described above for 24 hours. Nitrite levels in the culture supernatants were determined using the colorimetric Griess reaction (Sigma, St. Louis, MO, USA). Absorbance was measured with a plate reader at 550 nm. The concentration of nitrite (NO₂⁻) was determined from standard curves constructed with serial concentrations of sodium nitrite (NaNO₂).

**Bacterial cultures.** S. aureus (ATCC-6538; 0.5x10⁶ CFU/ml) and E. coli (ATCC-25922; 0.5x10⁶ CFU/ml) were cultured in Lysogeny Broth (LB) and treated as follow: LB (Negative Control), Penicillin/Streptomycin (Pen/Strep) 5X (5%) (Positive Control), PEL 10μg/ml, LAT 1μg/ml, PEL+LAT. These concentrations were chosen upon preliminary minimum inhibitory concentration (MIC) studies. The bacterial growth was evaluated measuring absorbance at 595 nm, at the following experimental times: 0-1-2-3-4-5-6-7-20 hours.

**Statistical Analysis.** Data are reported as scatter dot plots, showing the mean±SEM. Statistical differences were assessed with ONE-Way ANOVA followed by Bonferroni’s post-test, or TWO-Way ANOVA followed by Tukey’s multiple comparison post-test, as appropriate. p values less than 0.05 were considered as significant.

The statistical analysis was performed by using GraphPad prism 8.4.3 version (San Diego, USA).
Results

PEL and LAT combination showed anti-inflammatory activity.

Because we wanted to evaluate the anti-inflammatory activity of the combination of PEL and LAT, we first analyzed the single components with the objective to identify the suboptimal concentration to use in vitro. J774.1 murine macrophage cells were treated for 24 hours with serial concentrations of PEL (0.01-0.1-1-10-100μg/ml) or LAT (0.01-0.1-1-10-100μg/ml), in the presence or not of LPS (0.1μg/ml), a well-known pro-inflammatory stimulus [12, 13]. The anti-inflammatory activities were assessed by measuring the levels of IL-1β, a pro-inflammatory cytokine. The administration of the sole PEL (0.01-0.1-1-10-100μg/ml) (Figure 1A, black dots) did not alter the levels of IL-1β. In contrast, the addition of PEL on LPS-stimulated macrophages significantly reduced the levels of IL-1β at the concentration of 10-100 μg/ml (Figure 1A, red dots). Similarly, the administration of LAT alone did not alter the levels of IL-1β (Figure 1B, black dots). In contrast, the administration of LAT on LPS-treated macrophages significantly reduced the levels of IL-1β at the concentration of 1-10 μg/ml (Figure 1B, red dots).

The combination of LAT (1μg/ml) with PEL (10μg/ml) on LPS-treated macrophages still reduced the levels of IL-1β (Figure 1C, red dots). Because both PEL (63.65±10.7 pg/ml) and LAT (67.19±13.2 pg/ml) alone were able to reduce the levels of IL-1β in the presence of LPS (115.9±15.4 pg/ml), we compared these levels when both PEL and LAT were added in combination onto LPS-stimulated macrophages. The levels of IL-1β were still significantly reduced when PEL+LAT (52.74±8.5 pg/ml) were added onto LPS-treated macrophages compared to LPS alone (Figure 1C). In contrast, the sole addition of PEL+LAT on macrophages did not alter the levels of this cytokine (Figure 1C, black dots).

In order to rule out any alteration of cell viability, MTT assay was performed and did not show any statistical reduction of cell viability either after PEL+LAT or PEL+LAT+LPS addition (Figure 2).

Taken together, these data imply that the combination of PEL and LAT had anti-inflammatory activities as shown by the levels of IL-1β.

The combination of PEL and LAT showed anti-oxidant properties on LPS-treated macrophages.
To evaluate the anti-oxidant properties of the combination of PEL and LAT, J774.1 macrophagic cells were treated for 45 minutes with PEL (10μg/ml) or LAT (1μg/ml) or their combination in the presence or not of LPS (1μg/ml). The administration of the sole LAT or PEL (Figure 3A, black dots) did not alter the percentage of DCHF⁺ cells. Instead, the administration of LAT+PEL on LPS-treated macrophages significantly reduced the percentage of DCHF⁺ cells (Figure 3A, red dots). The percentage of DCHF⁺ cells after PEL+LAT addition on LPS-treated macrophages was two-fold decreased compared to the single PEL or LAT. Indeed, the percentage of DCHF⁺ cells after PEL+LAT+LPS were 3.28±1 %DCHF⁺ cells vs LPS that was 6.35±1.6 %DCHF⁺ cells (Figure 3A and Figure 3B). The sole PEL+LPS registered 6±1.75 %DCHF⁺ cells and LAT+LPS 4.28±1.5 %DCHF⁺ cells, implying that the combination was able to exert an additive anti-oxidant activity.

To further investigate the effect of the combination of PEL+LAT on the oxidative stress, the levels of nitrite were measured. Again, the administration of the sole PEL or LAT did not alter the levels of nitrite in cell-free supernatant (Figure 3C, black dots). In contrast, the addition of PEL+LAT robustly reduced the levels of nitrite from LPS-treated macrophages (Figure 3C, red dots). In particular, we measured the following levels of nitrite: LPS: 13.48±1.8 µM, PEL+LPS: 9.2±3.4 µM, LAT+LPS: 9.69±3.7 µM, PEL+LAT+LPS: 3.13±0.2 µM. The administration of PEL+LAT showed a potentiated pharmacological activity compared to the single compound.

Taken altogether, these data suggest that the combination of PEL+LAT exerted a potentiated anti-oxidant activity on LPS-treated macrophages.

**PEL+LAT combination had anti-microbial activities.**

It is already known that PEL and LAT have antimicrobial activities [3, 14]. However, the main goal of this study was to understand whether the combination of both could prove as antimicrobial drug. Therefore, we used Gram positive bacterium, *S. aureus* (0.5x10⁶ CFU/ml), and Gram negative bacterium, *E. coli* (0.5x10⁶ CFU/ml) cultures which were treated with LAT at the minimum inhibitory concentration (MIC) of 1μg/ml or PEL at the MIC of 10μg/ml. Bacterial growth was evaluated 1-2-3-4-5-6-7-20 hours after treatment.

We already proved that the administration of PEL showed bacteriostatic activities on both *S. aureus* and *E. coli* growth at the MIC of 10μg/ml, starting from 5 and 6 hours, respectively, after treatment compared to the control group [5].
The administration of LAT (1µg/ml) significantly reduced the growth of *S. aureus* starting from 6 hours post treatment compared to the control group (Figure 4A, red line vs black line). This effect was comparable to the activity of the mixture penicillin/streptomycin (Pen/Strep) (Figure 4A, blue line vs red line). However, LAT showed higher antimicrobial activity in terms of *S. aureus* growth compared to Pen/Strep mixture at 20 hours (Figure 4A, red line vs blue line). The combination of PEL+LAT showed an earlier activity (5 hours) (Figure 4B) than LAT alone (Figure 4A) in that the growth of *S. aureus* was reduced at 5 hours compared to 6 hours when LAT was added alone.

Similarly, the administration of LAT significantly reduced the growth of *E. coli* culture at 6 hours compared to the control group (Figure 5A, red line vs black line). The combination of PEL+LAT significantly reduce the growth of the *E. coli* culture at 6 hours post-treatment (Figure 5B). Interestingly, this effect was more pronounced than that observed for Pen/Strep at 20 hours (Figure 5B, blue line vs red line).
Discussion

The main goal of this study was to evaluate whether the combination of PEL and LAT could exert additive/synergistic pharmacological activities as anti-inflammatory, anti-oxidant and anti-microbial agents compared to the single components. Similarly to what reported in literature, we found that PEL and LAT used alone were able to reduce LPS-induced pro-inflammatory IL-1β, as well as reduce reactive oxygen species (ROS), nitrite and bacteria growth. More importantly, the combination of PEL with LAT showed an additive pharmacological activity in terms of anti-oxidant and anti-microbial activities.

IL-1β is widely described as a pro-inflammatory cytokine, released after LPS stimulation [15, 16]. Our data demonstrate that the combination of PEL+LAT significantly reduced the levels of IL-1β after LPS stimulation. This effect could prompt PELIRGOSTIM as an innovative and hitherto unknown combination, able to attenuate inflammation-related pathways. IL-1β is a critical regulator of the inflammatory response that, according to the activation of the inflammasome complex, its release can promote leukocyte migration with ensuing tissue damage, can promote T-cell survival, can contribute to the polarization of Th1, Th2 and Th17 differentiation. In addition, IL-1β induces IL-6 and/or TNF-α release, participating to the recruitment of other immune cells which phenotype can be endeavored according to the microenvironment [16]. However, our data has the limitation to prove the sole activity of the combination PEL+LAT to reduce IL-1β release, but future studies will be performed by using in vivo models to prove its anti-inflammatory activity. Nevertheless, we believe that the capability of PEL+LAT to reduce the release of IL-1β from LPS-treated macrophages, associated to the reduced oxidant activity, can be of beneficial in inflammatory-based disorders.

Indeed, another important characteristic of PEL+LAT combination is the anti-oxidant activity, which could be of potential relevance in oxidative stress-based pathologies, such as chronic obstructive pulmonary disease (COPD) [12, 17, 18]. In particular, we observed that PEL+LAT exerted a potentiated anti-oxidant activity on LPS-treated macrophages. Indeed, although the reduction of ROS (DCHF^+^ cells) and of nitrite by the single PEL or LAT, the combination PELIRGOSTIM was able to reduce the levels of ROS in a two-fold manner in the presence of LPS, as well as to reduce nitrite in a four-fold manner. This effect is of great clinical relevance especially in pathologies, during which the oxidative stress plays a pivotal role. Therefore, the identification of beneficial nutraceuticals, as in the case of PEL and LAT, could be important to prevent the
establishment of an oxidative status that leads cells to damage ensuing an inflammatory pattern that can be at the basis of the pathology.

Another important issue that deserves to be highlighted in this manuscript is that the combination of PEL and LAT exerted higher antimicrobial activity than LAT alone, well-known to be important during breast feeding [19]. PEL+LAT were able to statistically reduce S. aureus and E. coli growth, effect that was longer than that observed for penicillin/streptomycin. The administration of the single compounds still reduced bacteria growth; however, this effect was observed at 6 hours rather than at 5 hours. Moreover, this effect was not due to antioxidant activity of the single compounds as already reported [4, 20]. Indeed, the sole compounds were not able to exert anti-oxidant activities, rather, they showed bacteriostatic activity although at later time points. It has already been reported that LAT has strong anti-microbial activities against Gram positive and Gram negative bacteria as well as fungi, yeasts, viruses and protozoa [14]. The anti-microbial activity of LAT is generally associated to two mechanisms: the first is based on iron absorption in the site of infection, leading to the deprivation of nutrients to microbes; the second one is the direct contact of LAT with pathogens which interferes with microbial physiology [21]. In the latter case, the presence of positive amino acids in LAT chemical structure allows it to interact with negatively charged molecules on some bacterial, viral, fungal and parasite surfaces, causing cell lysis [21]. On the other hand, we already proved that PEL alone can exert anti-microbial activities [5]. Here, the combination of PEL and LAT led to an additive bacteriostatic activity, especially in the case of S. aureus. In addition, due to the recent emergency and spread of multidrug resistant pathogens, the combination of PEL and LAT could prove of innovative potentiality for the actual antimicrobial therapy.

Conclusion

In conclusion, although the limitation of an in vitro study, these data suggest that the combination PEL+LAT (PELIRGOSTIM) can reduce the release of pro-inflammatory cytokines, oxidants and bacteria growth, most likely preventing leukocyte chemiotaxis with a reduced inflammatory pattern. Therefore, our data pave the way for an innovative therapeutic approach for inflammation-, oxidative stress- and microbial-related disorders.
Author contribution

MT and CC performed the experiments; UDM provided the compounds; AB contributed to statistically analyze data, interpret data and revise the manuscript; AP and RS supervised the experimental protocol; MT wrote the manuscript; RS approved the final version of the manuscript.

Disclosure of Conflicts of Interest

MT, AP and RS disclose to be founders of ImmunePharma srl. UDM is founder of Shedir Pharma srl. AB is co-founder of Neilos srl. The other author does not disclose any conflict of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Figure Legends

Figure 1. Release of pro-inflammatory cytokines. Treatment of J774.1 murine macrophages with PEL (0.01-0.1-1-10-100µg/ml) (A), LAT (0.01-0.1-1-10-100µg/ml) (B) and PEL 10µg/ml+LAT 1µg/ml (C) in the presence or not of LPS. Black dots represent the release of IL-1β (A, B and C) after the single compound treatment, whereas the red dots represent the release of the cytokines in the presence of LPS (0.1µg/ml). Cells were treated for 24 hours. Data are represented as mean±SEM (n=5). Statistically significant differences were determined by ONE-way ANOVA followed by Bonferroni’s multiple comparison post-test.

Figure 2. Cell viability. MTT assay was performed after J774.1 murine macrophages were treated for 24 hours with PEL (10µg/ml) + LAT(1µg/ml) and PEL 10µg/ml + LAT 1µg/ml + LPS 0.1µg/ml. Data are represented as mean±SEM. No statistically significant differences were determined according to ONE-way ANOVA followed by Bonferroni’s multiple comparison post-test.

Figure 3. Release of reactive oxygen species and nitrite. Treatment of J774.1 murine macrophages with LAT (1µg/ml) and PEL (10µg/ml) in the presence or not of LPS at the concentration of 1µg/ml (A) and 0.1µg/ml (C). The different concentration of LPS was used in accordance to the levels of oxidants (A) and nitrite (C) produced. A) Black dots represent the percentage of DCHF²+ cells after the single compound treatment, whereas the red dots represent the percentage of DCHF⁺ cells in the presence of LPS. Cells were treated for 45 minutes. B) Representative flow histogram plots. C) Black dots represent the nitrite concentration after the single compound treatment, whereas the red dots represent the nitrite concentration in the presence of LPS. Cells were treated for 24 hours. Data are represented as mean±SEM (n=5). Statistically significant differences were determined by ONE-way ANOVA followed by Bonferroni’s multiple comparison post-test.

Figure 4. S. aureus growth. Treatment of S. aureus (0.5x10⁶ CFU/ml) culture with LAT (1µg/ml) (A) and PEL+LAT (B). The black line represents the control of the bacteria growth without antibiotic. The blue line represents bacteria growth with penicillin/streptomycin as antibiotic, and the red line represents the bacteria growth with LAT alone (A) or in combination with PEL (B). The bacteria growth was analyzed from 0 up to 20 hours. Data are represented as mean±SEM range
Statistically significant differences were determined by Two-way ANOVA followed by Tukey’s multiple comparison post-test.

**Figure 5. E. coli growth.** Treatment of *E. coli* (0.5x10^6 CFU/ml) culture with LAT (1µg/ml) (A) and PEL+LAT (B). The black line represents the control of the bacteria growth without antibiotic. The blue line represents bacteria growth with penicillin/streptomycin as antibiotic, and the red line represents the bacteria growth with the combination. The bacteria growth was analyzed from 0 up to 20 hours. Data are represented as mean±SEM range (n=9). Statistically significant differences were determined by Two-way ANOVA followed by Tukey’s multiple comparison post-test.
References

1. Moyo M, Van Staden J. Medicinal properties and conservation of Pelargonium sidoides DC. J Ethnopharmacol., 152(2):243-55, 2014.

2. Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol., 119(3):420-33, 2008.

3. Beil W, Kilian P. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine., 14 Suppl 6:5-8, 2007.

4. Pereira A, Bester M, Soundy P, Apostolides Z. Anti-proliferative properties of commercial Pelargonium sidoides tincture, with cell-cycle G0/G1 arrest and apoptosis in Jurkat leukaemia cells. Pharm Biol., 54(9):1831-40, 2016.

5. Terlizzi M, Colarusso C, Di Maio U, Pinto A, Sorrentino R. The combination of N-Acetyl-L-Cysteine, Pelargonium sidoides and Justicia adhatoda (NAXX) exerts bacteriostatic activity against S. aureus and E. coli. Nat Prod Res. (April 21, 2020) doi: 10.1080/14786419.2020.1761359.

6. Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. Int J Mol Sci.;18(9). pii: E1985, 2017.

7. Giansanti F, Panella G, Leboffe L, Antonini G. Lactoferrin from Milk: Nutraceutical and Pharmacological Properties. Pharmaceuticals (Basel), 9(4). pii: E61, 2016.

8. Li H, Wang Y, Yang H, Liu L, Wang J, Zheng N. Lactoferrin Induces the Synthesis of Vitamin B6 and Protects HUVEC Functions by Activating PDXP and the PI3K/AKT/ERK1/2 Pathway. Int J Mol Sci., 20(3). pii: E587, 2019.

9. Hao L, Shan Q, Wei J, Ma F, Sun P. Lactoferrin: Major Physiological Functions and Applications. Curr Protein Pept Sci. 2019;20(2):139-144.

10. Sorrentino R, Morello S, Chen S, Bonavita E, Pinto A. The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation. J Cell Physiol. 2010;223(1):158-67.

11. Issa R, Sorrentino R, Sukkar MB, Sriskandan S, Chung KF, Mitchell JA. Differential regulation of CCL-11/etoxin-1 and CXCL-8/IL-8 by gram-positive and gram-negative bacteria in human airway smooth muscle cells. Respir Res. 2008 Apr 1;9(1):30.

12. Colarusso C, Terlizzi M, Molino A, Imitazione P, Somma P, Rega R, Saccomanno A, Aquino RP, Pinto A, Sorrentino R. AIM2 Inflammasome Activation Leads to IL-1α and TGF-β Release From Exacerbated Chronic Obstructive Pulmonary Disease-Derived Peripheral Blood Mononuclear Cells. Front Pharmacol.;10:257, 2019.
13. Terlizzi M, Molino A, Colarusso C, Donovan C, Imitazione P, Somma P, Aquino RP, Hansbro PM, Pinto A, Sorrentino R. Activation of the Absent in Melanoma 2 Inflammasome in Peripheral Blood Mononuclear Cells From Idiopathic Pulmonary Fibrosis Patients Leads to the Release of Pro-Fibrotic Mediators. *Front Immunol.*;9:670, 2018.

14. Jenssen H, Hancock RE. Antimicrobial properties of lactoferrin. *Biochimie*; 91(1):19-29, 2009.

15. Rega A, Terlizzi M, Luciano A, Forte G, Crother TR, Arra C, Arditi M, Pinto A, Sorrentino R. Plasmacytoid dendritic cells play a key role in tumor progression in lipopolysaccharide-stimulated lung tumor-bearing mice. *J Immunol.*;190(5):2391-402, 2013.

16. Terlizzi M, Casolaro V, Pinto A, Sorrentino R. Inflammasome: cancer's friend or foe? *Pharmacol Ther.*;143(1):24-33, 2014.

17. Colarusso C, Terlizzi M, Molino A, Pinto A, Sorrentino R. Role of the inflammasome in chronic obstructive pulmonary disease (COPD). *Oncotarget.*;8(47):81813-81824, 2017.

18. De Falco G, Colarusso C, Terlizzi M, Popolo A, Pecoraro M, Commodo M, Minutolo P, Sirignano M, D'Anna A, Aquino RP, Pinto A, Molino A, Sorrentino R. Chronic Obstructive Pulmonary Disease-Derived Circulating Cells Release IL-18 and IL-33 under Ultrafine Particulate Matter Exposure in a Caspase-1/8-Independent Manner. *Front Immunol.*;8:1415, 2017.

19. Cai X, Duan Y, Li Y, Wang J, Mao Y, Yang Z, Zhao X, Zhao Y, Guan Y, Yin S. Lactoferrin level in breast milk: a study of 248 samples from eight regions in China. *Food Funct.*;9(8):4216-4222, 2018.

20. Safaeian L, Javanmard SH, Mollanoori Y, Dana N. Cytoprotective and antioxidant effect of human lactoferrin against H2O2-induced oxidative stress in human umbilical vein endothelial cells. *Adv Biomed Res.*, 4:188, 2015.

21. Sohrabi SM, Niazi A, Chahardoli M, Hortamani A, Setoodeh P. In silico investigation of lactoferrin protein characterizations for the prediction of anti-microbial properties. *Mol Biol Res Commun.*; 3(2):85-100, 2014.
Figure 1
Figure 2
Figure 3
Figure 4

A

S. aureus

- CTR
- Pen/Strep 5X
- LAT 1μg/ml

5h: CTR vs Pen/Strep p=0.0021
6h: CTR vs Pen/Strep p=0.0004
CTR vs LAT p=0.0077
7h: CTR vs Pen/Strep p<0.0001
CTR vs LAT p<0.0001
20h: CTR vs Pen/Strep p=0.0004
CTR vs LAT p<0.0001
Pen/Strep vs LAT p=0.0006

B

S. aureus

- CTR
- Pen/Strep 5X
- PEL+LAT

5h: CTR vs Pen/Strep p=0.0018
CTR vs P+L p=0.0347
6h: CTR vs Pen/Strep p=0.0001
CTR vs P+L p=0.003
7h: CTR vs Pen/Strep p<0.0001
CTR vs P+L p<0.0001
20h: CTR vs Pen/Strep p=0.0001
CTR vs P+L p<0.0001
Pen/Strep vs P+L p<0.0001
Figure 5

A  E. coli

- CTR
- Pen/Strep 5X
- LAT

| Time (hours) | CTR vs Pen/Strep p-value |
|-------------|--------------------------|
| 3h          | 0.0217                   |
| 4h          | 0.0006                   |
| 5h          | 0.0004                   |
| 6h          | 0.0001                   |
| 7h          | 0.0036                   |
| 20h         | 0.0025                   |
| Pen/Strep vs LAT p-value | 0.0001 |

B  E. coli

- CTR
- Pen/Strep 5X
- PEL+LAT

| Time (hours) | CTR vs Pen/Strep p-value |
|-------------|--------------------------|
| 3h          | 0.0237                   |
| 4h          | 0.0007                   |
| 5h          | 0.0005                   |
| 6h          | 0.0001                   |
| 7h          | 0.0046                   |
| 20h         | 0.0028                   |
| Pen/Strep vs P+L p-value | 0.0001 |
| Pen/Strep vs LAT p-value | 0.0001 |